<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02136927</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_12_10</org_study_id>
    <nct_id>NCT02136927</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane速 in Subjects With Locally Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>A Randomized, Open Label, Two Period, Single Dose, Two Way Crossover, Bioavailability Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) and Abraxane速 in Subjects With Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to characterize pharmacokinetics and bioequivalence of PICN
      and Abraxane速, with safety evaluation
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Pre-dose, post-dose up to 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Samples will be collected from all subjects at scheduled time-points: pre-dose and up to 3 days post-dose.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 3</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>AEs encountered following dosing with PICN or Abraxane速 will be recorded as per CTCAE, Version 4.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PICN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After reconstitution, PICN will be administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abraxane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PICN</intervention_name>
    <arm_group_label>PICN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>260 mg/m2 every 3-weekly</description>
    <arm_group_label>Abraxane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has given written, informed consent and is available for the entire
             study.

          -  Histologically or cytologically confirmed diagnosis of breast cancer;

          -  Locally recurrent or metastatic breast cancer for which taxane-based therapy is a
             rational treatment option;

          -  Age 18 years or more

        Exclusion Criteria:

          -  Known hypersensitivity to both the study drugs or its excipients (Cholesteryl
             sulfate, Caprylic acid, Polyvinylpyrrolidone, Ethanol or Polyethylene glycol);

          -  Presence of clinically evident active CNS metastases, including leptomeningial
             involvement, requiring steroid or radiation therapy;

          -  Pre-existing clinically significant peripheral neuropathy (Grade 2 or higher
             according to CTCAE, Version 4.0);

          -  Any other severe concurrent disease which in the judgment of the investigator would
             make the subject inappropriate for entry into this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MNJ Institute of Oncology and Regional Cancer Center</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Malladi Krishna, MBBS,DNB,MD</last_name>
      <phone>40-23318414,23318424</phone>
      <email>rkmalladi@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Malladi Krishna, MBBS,DNB,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BIBI General Hospital and Cancer Centre</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500024</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Venkat Satya Suresh Attili, MBBS,MD,DM</last_name>
      <phone>040-24528122</phone>
      <email>sureshattili@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Venkat Satya Suresh Attili, MBBS,MD,DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shyam Aggarwal, MBBS,MD (Medicine)</last_name>
      <phone>011-25861002</phone>
      <email>drshyam_aggarwal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shyam Aggarwal, MBBS,MD (Medicine)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kailash Cancer Hospital and Research Center</name>
      <address>
        <city>Goraj</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niraj Bhatt, MBBS,MD (General Medicine),DM</last_name>
      <phone>91-2668-268040-50</phone>
      <email>nirajbhatt1974@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Niraj Bhatt, MBBS,MD (General Medicine),DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences (AIMS)</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavithran Keechilat, MBBS,MD,DM</last_name>
      <phone>0484-4003003</phone>
      <email>pavithrank@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Pavithran Keechilat, MBBS,MD,DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jyoti , Bajpai</last_name>
      <phone>022-24177287</phone>
      <email>dr_jyotibajpai@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Jyoti Bajpai, MBBS,MD,DM (Medical Oncology)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central India Cancer Research Institute</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ajay Mehta, MBBS.MS</last_name>
      <phone>ajayonco@hotmail.com</phone>
    </contact>
    <investigator>
      <last_name>Ajay Mehta, MBBS.MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shatabdi Super Specialty Hospital,</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shailesh Bondarde, MBBS,MD (Medicine)</last_name>
      <phone>0253-2501888</phone>
      <email>shaileshbondarde@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shailesh Bondarde, MBBS,MD (General Medicine),DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chetan Dilip Deshmukh, MD</last_name>
      <phone>66023000</phone>
      <email>drchetandeshmukh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chetan Deelip Deshmukh, MBBS,MD,DM (Medical Oncology)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KEM Hospital Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minish Jain, MBBS,MD (General Medicine)</last_name>
      <phone>020 66037336</phone>
      <email>drminishjain@yahoo.in</email>
    </contact>
    <investigator>
      <last_name>Minish Jain, MBBS,MD (General Medicine)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr.Kamakshi Memorial Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600100</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Venkatesan Srinivasan, MBBS,MCCP,MDRT,FIPM</last_name>
      <phone>044-22469200,66300300</phone>
      <email>vsrinivasan09@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Venkatesan Srinivasan, MBBS,MCCP,MDRT,FIPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital and Research Centre</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirushna Kumar Subramanian, MBBS,MD</last_name>
      <phone>0452-2588741-750</phone>
      <email>drkskk@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Kirushna Kumar Subramanian, MBBS,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
